RSS Feed Print
Head device using electromagnetic waves
Keep It 100
Posted: Thursday, September 19, 2019 10:31 AM
Joined: 2/26/2017
Posts: 443

Does anyone know anything about this?

The open-label study was a single center, single arm trial in eight patients 63 years of age and older with mild to moderate Alzheimer’s disease (AD) to evaluate the safety and initial efficacy of Transcranial Electromagnetic Treatment (TEMT). Patients were enrolled at the University of South Florida Health/Byrd Alzheimer’s Institute, which also conducted most clinical study assessments. Treatment was administered in the patient’s home by a caregiver (spouse, relative), using the MemorEM device.

Patients received TEMT for one-hour periods twice daily for two months. Although limitations of this study include the small number of subjects, not having a control group, and being of relatively short treatment duration, 120 treatments were administered in-home and the cognitive benefits observed were clinically important/meaningful at the highest levels. Providing additional credibility to the observed cognitive enhancements were the beneficial changes in AD markers in blood and CSF, as well as the enhancement in brain MRI imaging.

Lane Simonian
Posted: Thursday, September 19, 2019 10:45 AM
Joined: 12/12/2011
Posts: 4567

A biotech commentator sent me this link to the study:

This one confounds me.  Some electromagnetic stimulation may be good for the brain, but too much is not (the authors' claim that what they are using is safe and effective).

I don't see this holding up over the long-term, but I could certainly be wrong.

Posted: Thursday, September 19, 2019 11:10 AM
Joined: 2/17/2019
Posts: 190

I've seen studies on TCDS TransCranial direct stimulation. Its being tried for Parkinsons, Tinnitus, I haven't really looked into it, here's a link.

Radiolab has an episode called 9 volt nirvana, I haven't heard it yet, but it sound interesting.


Posted: Thursday, September 19, 2019 11:52 PM
Joined: 2/17/2019
Posts: 190

the tests also showed that their ADAS-cog score, which assesses their memory, thinking, judgment and other cognitive skills, was raised by 4 points or more in 7/8 patients.

 This score is used as the gold standard for judging the efficacy of all AD treatments, and the four-point increase shows a large increase in cognitive performance which translates into clinically important improvement in mental function.

This is all the more satisfying when it is contrasted with the typical 4+ decline in this score over one year in patients with AD. 

In other words, it could be interpreted as turning the clock back one whole year on the disease – a significant improvement in cognitive performance.